$CORT earnings report

Revenue of $340.5 million, a 64 percent increase over the same period in 2025; net income of $126.8 million; reiterated 2026 revenue guidance of $1.1 – $1.2 billion. AlphAI read Corcept Therapeutics's third quarter 2026 filing as strong. 2 quarters are on record below.

third quarter 2026

AlphAI · Earnings readCORT · third quarter 2026 · ended September 30, 2026

Revenue of $340.5 million, a 64 percent increase over the same period in 2025; net income of $126.8 million; reiterated 2026 revenue guidance of $1.1 – $1.2 billion.

✓Strong quarter

Third-quarter product revenue was $340.5 million, net income was $126.8 million, and Lifyorli contributed $91.4 million of revenue following its April 1st launch. The company reiterated 2026 revenue guidance of $1.1 – $1.2 billion.

Revenue
$340M
64 percent y/y
Korlym and authorized generic (three months ended September 30) (In thousands)
$249M
increased 19 percent q/q
2026 outlook
$1.1 – $1.2 billion

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Product revenue, net (three months ended September 30) (In thousands)GAAP$340.5M–64 percent
Cost of sales (three months ended September 30) (In thousands)GAAP4.61M––
Research and development (three months ended September 30) (In thousands)GAAP56.71M––
Selling, general and administrative (three months ended September 30) (In thousands)GAAP164.4M––
Total operating expenses (three months ended September 30) (In thousands)GAAP225.7M––
Income from operations (three months ended September 30) (In thousands)GAAP114.7M––
Interest and other income (three months ended September 30) (In thousands)GAAP5.58M––
Income before income taxes (three months ended September 30) (In thousands)GAAP120.3M––
Income tax benefit (three months ended September 30) (In thousands)GAAP6.47M––
Net income (three months ended September 30) (In thousands)GAAP$126.8M––
Net income attributable to common stockholders (three months ended September 30) (In thousands)GAAP$124.5M––
Basic net income per common share (three months ended September 30)GAAP$ 1.17––
Diluted net income per common share (three months ended September 30)GAAP$ 1.01––
Weighted-average shares outstanding used in computing net income per common share, basic (three months ended September 30) (In thousands)GAAP106.6M––
Weighted-average shares outstanding used in computing net income per common share, diluted (three months ended September 30) (In thousands)GAAP123.2M––
Product revenue, net (nine months ended September 30) (In thousands)GAAP$761.5M––
Cost of sales (nine months ended September 30) (In thousands)GAAP11.55M––
Research and development (nine months ended September 30) (In thousands)GAAP176.9M––
Selling, general and administrative (nine months ended September 30) (In thousands)GAAP466.7M––
Total operating expenses (nine months ended September 30) (In thousands)GAAP655.1M––
Income from operations (nine months ended September 30) (In thousands)GAAP106.4M––
Interest and other income (nine months ended September 30) (In thousands)GAAP15.1M––
Income before income taxes (nine months ended September 30) (In thousands)GAAP121.5M––
Income tax benefit (nine months ended September 30) (In thousands)GAAP16.48M––
Net income (nine months ended September 30) (In thousands)GAAP$138.0M––
Net income attributable to common stockholders (nine months ended September 30) (In thousands)GAAP$135.5M––
Basic net income per common share (nine months ended September 30)GAAP$ 1.28––
Diluted net income per common share (nine months ended September 30)GAAP$ 1.13––
Weighted-average shares outstanding used in computing net income per common share, basic (nine months ended September 30) (In thousands)GAAP105.5M––
Weighted-average shares outstanding used in computing net income per common share, diluted (nine months ended September 30) (In thousands)GAAP119.4M––

Segments

SegmentRevenueq/qy/y
Korlym and authorized generic (three months ended September 30) (In thousands)Awareness of the importance of diagnosing and treating patients with Cushing’s syndrome is steadily increasing.$249.1Mincreased 19 percent–
Lifyorli (three months ended September 30) (In thousands)Lifyorli’s uptake in ovarian cancer has been both very rapid and broad.91.41Mgrew 92 percent–
Korlym and authorized generic (nine months ended September 30) (In thousands)Endocrinology business growth was attributed to increasing awareness of diagnosing and treating Cushing’s syndrome.$622.6M––
Lifyorli (nine months ended September 30) (In thousands)Lifyorli was introduced in March 2026 as a treatment for patients with platinum-resistant ovarian cancer.139.0M––

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

2026 outlook

  • Revenue$1.1 – $1.2 billion
  • NoteRelacorilant for patients with Cushing’s syndrome resubmitted New Drug Application PDUFA date of December 17, 2026.
  • NoteBELLA Part B results expected by the end of next year.
  • NoteBELLA Part C results expected by the end of next year.
  • NoteTRIDENT results expected by the end of next year.
  • NoteEuropean Commission approval of the MAA for relacorilant plus nab-paclitaxel expected by the end of this year.
  • NoteProstate cancer Phase 2 results expected by the end of next year.
  • NoteSYNERGY results expected by the end of next year.
  • NoteA Phase 2 trial of miricorilant at 100 mg daily is starting soon.
  • NoteALS Phase 3 trial planned to begin next year.

Capital returns

  • The September 30, 2026 cash and investments balance reflects the acquisition of $43.7 million of common stock in the third quarter pursuant to the company’s stock repurchase program.
  • The September 30, 2026 cash and investments balance also reflects shares acquired upon the exercise of employee stock options and the vesting of restricted stock grants.

What drove it

  • Korlym and authorized generic product revenue was $249.1 million.
  • Lifyorli product revenue was $91.4 million.
  • Since its April 1st launch, more than 2,300 patients have received Lifyorli and more than 1,700 physicians have prescribed it.
  • BELLA Part A in 95 patients with platinum-resistant ovarian cancer reported median PFS of 7.2 months, ORR of 59 percent and OS of 88 percent at 6-months.
  • Among BELLA Part A patients with no prior bevacizumab, median PFS was 8.1 months, ORR was 66 percent and 6-month OS was 91 percent.
  • DAZALS exploratory analyses reported an 84 percent reduction in risk of death during the first year for patients receiving dazucorilant 300 mg versus placebo, with hazard ratio: 0.16, p-value: 0.0009.

Concerns

  • Selling, general and administrative expense was 164,431 (In thousands) in the third quarter, compared to 123,977 (In thousands) in the same period in 2025.
  • The release states median OS was not yet reached at the time of the BELLA Part A primary analysis.
  • MONARCH Cohort A reported an improvement in fibrosis of 19 percent at 48 weeks among patients who received pre- and post-treatment liver biopsies.
  • The FDA decision on the resubmitted NDA for relacorilant for patients with Cushing’s syndrome is expected by December 17, 2026.

What to watch

  • FDA decision on the relacorilant NDA for patients with Cushing’s syndrome on December 17, 2026.
  • European Commission decision on the MAA for relacorilant plus nab-paclitaxel for platinum-resistant ovarian cancer, expected by the end of this year.
  • BELLA Part B, BELLA Part C, TRIDENT, prostate cancer Phase 2 and SYNERGY results expected by the end of next year.
  • The planned Phase 3 ALS study next year and the planned higher-dose miricorilant Phase 2 trial.

Balance sheet and cash flow

  • Cash and investments were $662.3 million at September 30, 2026, compared to $544.6 million at June 30, 2026.
  • Cash and investments (In thousands): $ 662,307 at September 30, 2026; $ 532,422 at December 31, 2025.
  • Trade receivables, net of allowances (In thousands): 111,061 at September 30, 2026; 59,786 at December 31, 2025.
  • Inventory (In thousands): 37,569 at September 30, 2026; 23,962 at December 31, 2025.
  • Operating lease right-of-use asset (In thousands): 6,517 at September 30, 2026; 4,583 at December 31, 2025.
  • Deferred tax assets, net (In thousands): 169,069 at September 30, 2026; 168,197 at December 31, 2025.
  • Other assets (In thousands): 47,504 at September 30, 2026; 47,701 at December 31, 2025.
  • Total assets (In thousands): $ 1,034,027 at September 30, 2026; $ 836,651 at December 31, 2025.
  • Accounts payable (In thousands): $ 21,924 at September 30, 2026; $ 40,444 at December 31, 2025.
  • Operating lease liabilities (In thousands): 8,991 at September 30, 2026; 6,107 at December 31, 2025.
  • Other liabilities (In thousands): 169,372 at September 30, 2026; 142,295 at December 31, 2025.
  • Stockholders’ equity (In thousands): 833,740 at September 30, 2026; 647,805 at December 31, 2025.
  • Total liabilities and stockholders’ equity (In thousands): $ 1,034,027 at September 30, 2026; $ 836,651 at December 31, 2025.

Analysis

Corcept reported third-quarter 2026 product revenue of $340.5 million, which the release described as a 64 percent increase over the same period in 2025. Product revenue was $340,472 thousand in the financial statements, compared with $207,638 thousand in the prior-year quarter and $256.1 million in the second quarter of 2026. Net income was $126.8 million, versus $19.7 million in the third quarter of 2025 and $43.0 million in the second quarter of 2026. Diluted net income per common share was $1.01, compared with $0.16 in the prior-year quarter.

The revenue mix now includes a material contribution from Lifyorli. Korlym and authorized generic revenue was $249.1 million and was stated to have increased 19 percent, while Lifyorli generated $91.4 million and was stated to have grown 92 percent. Management linked endocrinology growth to increased awareness of diagnosis and treatment of Cushing’s syndrome, while describing Lifyorli uptake as rapid and broad. Since the April 1st launch, the company said more than 2,300 patients had received Lifyorli and more than 1,700 physicians had prescribed it.

Operating expenses were $225.7 million in the quarter, compared with $214.8 million in the second quarter of 2026. Within the quarter, research and development expense was 56,709 thousand, below 68,846 thousand in the third quarter of 2025, while selling, general and administrative expense was 164,431 thousand, above 123,977 thousand. Income from operations was 114,724 thousand, compared with 10,219 thousand in the prior-year quarter. Cash and investments increased by $117.7 million during the quarter to $662.3 million, notwithstanding $43.7 million of common-stock acquisitions under the repurchase program.

Clinical updates included BELLA Part A results in platinum-resistant ovarian cancer, with reported median PFS of 7.2 months, ORR of 59 percent and OS of 88 percent at 6-months. The company also reported that median OS had not yet been reached at the primary analysis. Regulatory and development milestones include a December 17, 2026 PDUFA date for relacorilant in Cushing’s syndrome, an expected European Commission decision by year-end for relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer, and multiple trial readouts expected by the end of next year.

Corcept reiterated 2026 revenue guidance of $1.1 – $1.2 billion. The filing did not provide forward guidance for gross margin, operating expenses, tax rate, earnings per share, cash flow or capital expenditures. The main reported operating indicators to monitor are continued Korlym and authorized generic growth, the trajectory of Lifyorli revenue after launch, spending levels, regulatory decisions, and the timing of clinical data from BELLA Parts B and C, TRIDENT, the prostate cancer trial and SYNERGY.

Management, verbatim

Awareness of the importance of diagnosing and treating patients with Cushing’s syndrome is steadily increasing and is driving the growth of our endocrinology business.

Joseph K. Belanoff, MD, Chief Executive Officer

Lifyorli’s uptake in ovarian cancer has been both very rapid and broad. Since its April 1st launch, more than 2,300 patients have received the medication. More than 1,700 physicians have prescribed it. We expect continued growth in both businesses and have reiterated our 2026 revenue guidance of $1.1 – $1.2 billion.

Joseph K. Belanoff, MD, Chief Executive Officer

Our BELLA Part A results provide the latest evidence of GR antagonism’s versatility, especially when administered earlier in the course of disease.

Bill Guyer, PharmD, Chief Development Officer

Not in the filing

stated, not guessed
  • Prior outlook section was not provided, so comparison of actual results with prior guidance is unavailable.
  • Gross margin was not reported.
  • Non-GAAP financial measures were not reported.
  • Operating cash flow was not reported.
  • Free cash flow was not reported.
  • Debt was not reported.
  • Dividend information was not reported.
  • Forward guidance for gross margin was not reported.
  • Forward guidance for operating expenses was not reported.
  • Forward guidance for tax rate was not reported.
  • Forward guidance for earnings per share was not reported.
  • Forward guidance for cash flow or capital expenditures was not reported.
  • Prior-quarter values were not reported for individual income-statement line items other than product revenue, total operating expenses and net income.
  • Year-over-year percentage changes were not reported for individual product revenue categories or individual income-statement expense line items.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

second quarter 2026

AlphAI · Earnings readCORT · second quarter 2026 · ended June 30, 2026

Revenue of $256.1 million, a 32 percent increase over the same period in 2025; 2026 revenue guidance increased to $1.1 – $1.2 billion.

✓Strong quarter

Second-quarter revenue increased 32 percent over the same period in 2025, Lifyorli contributed $47.6 million in its first quarter of availability, net income increased to $43.0 million, and the company increased 2026 revenue guidance to $1.1 – $1.2 billion.

Revenue
$256M
32 percent increase y/y
Korlym and authorized generic product
$209M
2026 outlook
$1.1 – $1.2 billion

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Revenueother$256.1M–32 percent increase
Operating expensesother$214.8M––
Net incomeother$43M––
Net income per common share (diluted)other$0.36––
Cash and investmentsother$544.6M––

Segments

SegmentRevenueq/qy/y
Korlym and authorized generic productThe company said its Cushing’s syndrome business had a record number of new prescriptions written for its medications as physicians increasingly recognize hypercortisolism’s true prevalence and the necessity of appropriate treatment.$208.6M––
Lifyorli productLifyorli generated revenue in its first quarter of availability. The company said over 1,300 patients had started treatment following FDA approval in March 2026 and that demand accelerated each month.$47.6M––

2026 outlook

  • Revenue$1.1 – $1.2 billion

What drove it

  • Revenue was $256.1 million, a 32 percent increase over the same period in 2025.
  • Korlym and authorized generic product revenue was $208.6 million.
  • Lifyorli product revenue was $47.6 million in its first quarter of availability.
  • Over 1,300 patients have started treatment with Lifyorli following FDA approval in March 2026.
  • The company increased 2026 revenue guidance to $1.1 – $1.2 billion.
  • The FDA approved Lifyorli plus nab-paclitaxel for platinum-resistant ovarian cancer in March 2026, and the regimen was added to NCCN Guidelines as a preferred regimen in April 2026.

Concerns

  • Second quarter 2026 operating expenses were $214.8 million, compared to $167.8 million in the same period in 2025, due to increased spending to launch Lifyorli and investments in the Cushing’s syndrome business.
  • The relacorilant NDA for Cushing’s syndrome has a PDUFA date of December 17, 2026.
  • BELLA Part A results, MONARCH results and a European Medicines Agency decision are expected by the end of this year.
  • Multiple oncology studies and the SYNERGY study are expected to produce results by the end of next year.

What to watch

  • Decision on the resubmitted relacorilant NDA for Cushing’s syndrome by December 17, 2026.
  • Expected European Medicines Agency approval decision for relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer later this year.
  • BELLA Part A results in platinum-resistant ovarian cancer by the end of this year.
  • MONARCH Phase 2b MASH results by the end of this year.
  • Planned start of a Phase 3 dazucorilant trial in patients with ALS early next year.
  • Results from BELLA Part B, BELLA Part C, STELLA, TRIDENT and SYNERGY by the end of next year.

Balance sheet and cash flow

  • Cash and investments were $544.6 million at June 30, 2026, compared to $515.4 million at March 31, 2026.

Analysis

Corcept reported second-quarter 2026 revenue of $256.1 million, compared to $194.4 million in the second quarter of 2025, representing a reported 32 percent increase. The result reflects contributions from both commercial businesses: Korlym and authorized generic product revenue was $208.6 million, while Lifyorli product revenue was $47.6 million in its first quarter of availability. Management said more than 1,300 patients had started Lifyorli after its March 2026 FDA approval and that demand accelerated each month.

The Cushing’s syndrome franchise remained the larger revenue contributor. Management said the business recorded a record number of new prescriptions, citing increasing physician recognition of hypercortisolism’s prevalence and the need for treatment. The company expects this trend to continue as CATALYST and MOMENTUM findings are incorporated into clinical practice. Lifyorli’s launch is the principal new mix factor, with the company highlighting physician response to its efficacy and safety profile, oral administration and lack of biomarker requirement.

Profitability remained positive despite investment. Operating expenses were $214.8 million, compared to $167.8 million in the same period in 2025, due to spending for the Lifyorli launch and investments in the Cushing’s syndrome business. Net income was $43.0 million, compared to $35.1 million in second quarter 2025, and diluted net income per common share was $0.36, compared to $0.29. The filing does not provide gross margin, operating income, operating cash flow or free cash flow figures in the supplied text, limiting visibility into margin and cash conversion.

Liquidity increased during the period, with cash and investments of $544.6 million at June 30, 2026, compared to $515.4 million at March 31, 2026. The supplied text does not disclose debt, share repurchases, dividends or other capital-return activity. The company raised 2026 revenue guidance to $1.1 – $1.2 billion, signaling management’s expectation for continued strength across its oncology and Cushing’s syndrome businesses.

Clinical and regulatory execution remains central to the outlook. The resubmitted relacorilant NDA for Cushing’s syndrome has a PDUFA date of December 17, 2026. The company also expects a European Medicines Agency decision, BELLA Part A results and MONARCH results by the end of this year. Additional oncology study results are expected by the end of next year, while a Phase 3 dazucorilant trial in ALS is planned to begin early next year.

Management, verbatim

Our oncology and Cushing’s syndrome businesses delivered strong results in the second quarter.

Joseph K. Belanoff, M.D., Chief Executive Officer

We anticipate continued strength across our businesses and have increased our 2026 revenue guidance to $1.1 – $1.2 billion.

Joseph K. Belanoff, M.D., Chief Executive Officer

Relacorilant has the potential to become the new standard of care.

Bill Guyer, PharmD, Chief Development Officer

Not in the filing

stated, not guessed
  • GAAP or non-GAAP designation for reported financial metrics
  • Gross profit
  • Gross margin
  • Operating income
  • Operating margin
  • Non-GAAP revenue, earnings, EPS or margin measures
  • Operating cash flow
  • Free cash flow
  • Debt
  • Share repurchases
  • Dividends
  • Diluted weighted-average shares outstanding
  • Prior-quarter revenue
  • Prior-quarter operating expenses
  • Prior-quarter net income
  • Prior-quarter diluted net income per common share
  • Percentage changes for operating expenses, net income and diluted net income per common share
  • 2026 guidance for gross margin
  • 2026 guidance for operating expenses
  • 2026 guidance for tax rate
  • Prior 2026 revenue-guidance range

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about CORT earnings dates

When is Corcept Therapeutics's next earnings date?
AlphAI has no date for CORT yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.